Celsius Therapeutics, Inc.

Celsius Therapeutics, Inc. specializes in innovative therapeutic solutions for immune-mediated diseases, focusing on biologic therapies that leverage genomic technologies to enhance patient outcomes and quality of life. Founded in 2018 and headquartered in Cambridge, US, Celsius Therapeutics develops therapies targeting immune-mediated diseases. The company was recently acquired by AbbVie for USD 250 mn, enhancing its capacity to deliver advanced treatments.

CEO Tariq Kassum leads the firm, which has completed 4 deals including a Trade Sale on June 27, 2024, totaling USD 250 mn raised to date. Celsius Therapeutics, now part of AbbVie, specializes in developing therapies for immune-mediated diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Their products employ genomic technologies to modulate immune responses, targeting specific pathways to improve patient outcomes. The company markets its therapies primarily in the US and Europe, focusing on urban centers with high demand for advanced treatments.

Celsius Therapeutics generates revenue through direct sales of its biologic therapies, primarily dispensed via healthcare providers and specialty pharmacies. The pricing reflects the advanced nature of the products, determined by development costs and therapeutic benefits. This revenue model supports ongoing demand for effective solutions in the biopharmaceutical market. The recent acquisition by AbbVie aims to leverage the development of CEL383, targeting new treatment options for inflammatory bowel disease (IBD) patients.

The company plans to expand its market presence and introduce innovative products designed to enhance treatment efficacy. The funding from the acquisition will support these initiatives, focusing on scaling operations and development efforts through 2024.